AwesomeCapital
Search This Blog
Thursday, February 27, 2020
Esperion Therapeutics EPS beats by $0.49, misses on revenue
Esperion Therapeutics (NASDAQ:
ESPR
): Q4 GAAP EPS of -$2.26
beats by $0.49
.
Revenue of $0.98M
misses by $0.01M
.
Press Release
https://seekingalpha.com/news/3546372-esperion-therapeutics-eps-beats-0_49-misses-on-revenue
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.